ACT Genomics raises $12.5 mln in Series B led by Hotung Group and CDIB
Hotung Group and CDIB Capital Management led a $12.5 million Series B funding in ACT Genomics. Based in Taipei, ACT provides genomic profiling assays and molecular information to oncologists and biopharmaceutical clients. Existing investors Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital also participated.
6 May 2016•1 min read
